Martin-Luther-Universitaet Halle-Wittenberg

6 trials 2 recruiting Academic / non-commercial

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

3 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 1 Phase II: 1 Phase I/II: 1 Phase IV: 3

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Myelofibrosis 1

Top IMPs

AZACITIDINE 1 CHORIONIC GONADOTROPHIN 1 FARICIMAB 1 FEDRATINIB 1 FOLLITROPIN ALFA 1 NIMODIPINE 1 RAMUCIRUMAB 1 SODIUM CHLORIDE 1 TRANEXAMIC ACID 1

All trials

6 total

A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa o… Pending

2025-525005-20-00 Phase IV 3 countries CHORIONIC GONADOTROPHIN; FOLLITROPIN ALFA
A phase IV study of Faricimab to explore associations of visual acuity benefits and changes in vascular integrity using adaptive optics in p… Recruiting

2023-509829-52-00 Phase IV 1 country FARICIMAB
Tranexamic Acid for reduction of intra- and postoperative TRansfusion requirements in elective Abdominal surgery: randomized controlled tria… Recruiting

2023-509970-43-01 Phase IV 1 country SODIUM CHLORIDE; TRANEXAMIC ACID
Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended

2024-519227-22-00 Phase I/II 1 country AZACITIDINE; FEDRATINIB
Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial (A… Ended

2024-518182-10-00 Phase III 1 country NIMODIPINE
A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastat… Ended

2024-515045-42-00 Phase II 1 country RAMUCIRUMAB

Showing 1–6 of 6 trials

← All sponsors A–Z